Andrew Saik
CIK 1616284 · Chief Financial Officer · last filed 2026-06-24
Andrew Saik is a Chief Financial Officer who has filed 42 SEC Form 4 insider transactions across 8 companies since 2014. The most recent filing shows the insider sold $46.5K of ARVN on Jun 24, 2026. Across all open-market trades the lifetime net is −$203.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.57M
8
42
-$203.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARVN | Chief Financial Officer | 187,432 | $8.20 | $1.54M | -$261.6K | 8 | 2026-06-24 |
| MIST | Director | — | $1.07 | — | $0 | 4 | 2026-06-12 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | EVP & Chief Financial Officer | 68,265 | $19.00 | $1.30M | $0 | 10 | 2023-09-25 |
| VYNE | Chief Financial Officer | 129 | $28.56 | $3.7K | $58.5K | 4 | 2021-06-02 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Financial Officer | 300,000 | — | — | $0 | 2 | 2020-05-08 |
| PDSB | Chief Financial Officer | 42,549 | $0.69 | $29.4K | $0 | 3 | 2020-02-19 |
| EDGE | Chief Financial Officer | — | $49.76 | — | $0 | 4 | 2018-08-15 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | CFO | 0 | — | — | $0 | 2 | 2015-01-30 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | ARVN | Sell (S) | −5,696 | -$46.5K | EDGAR |
| 2026-06-23 | ARVN | Notice (144) | −5,846 | -$47.6K | EDGAR |
| 2026-06-12 | MIST | Grant (A) | — | $0 | EDGAR |
| 2026-05-13 | ARVN | Sell (S) | −11,139 | -$110.7K | EDGAR |
| 2026-05-08 | ARVN | Notice (144) | −11,343 | -$114.7K | EDGAR |
| 2026-03-02 | ARVN | Grant (A) | +45,000 | $0 | EDGAR |
| 2026-02-18 | ARVN | Sell (S) | −5,134 | -$61.0K | EDGAR |
| 2026-02-13 | ARVN | Notice (144) | −5,134 | -$61.1K | EDGAR |
| 2025-06-24 | ARVN | Sell (S) | −5,700 | -$43.4K | EDGAR |
| 2025-06-23 | ARVN | Notice (144) | −5,927 | -$43.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.